SEC Tracker
Get the app

Amarin AMRN

Amarin FY 2020: revenue $614.1M; diluted EPS −$0.05

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Amarin reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$614.1MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$18.0MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$0.05No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$187.0MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$21.7MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Amarin files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
  2. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
  3. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  4. Emergent BioSolutions EBS public float $343M, Jun 30, 2025
  5. Altimmune ALT public float $327M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.